Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NRG-103 for Recurrent Glioblastoma
NCT06757153Phase 1Recruiting
- Sponsor
- Zhongnan Hospital of Wuhan University
- Start
- Dec 2024
- Primary completion
- Aug 2027
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NRG-103 in glioblastoma (GBM), sponsored by Zhongnan Hospital of Wuhan University. Primary endpoint: Progression-free survival at 6 months. Started Dec 2024; status: recruiting.
02
Drugs
NRG-103
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT06757153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06757153.